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pportunity to save lives. Furthermore, no integrated analyses exist
f combined microbiological/virological, immunological, clinical,
pidemiological, and genetic data for comprehensive assessment
f host-emerging pathogen interactions that can inform preven-
ion and control activities, and guide clinical management. There
s an urgent need to establish a sustainable consortium of clin-
cal research groups with broad geographic coverage (including
ow resource settings), cross-border coordination, commitment to
pen access, and capacity to conduct complementary high-quality,
ospital-based pathogenesis and clinical management studies and
he ﬂexibility to respond immediately to rapidly emergent threats.
e need a new paradigm for clinical research in the context of
apidly emerging public health threats and one appropriate to the
orts of challenges we will face in the 21st Century.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.112
ype: Invited Presentation
inal Abstract Number: 26.003
ession: Initiatives for the Control of Infectious Diseases
ate: Friday, June 15, 2012
ime: 15:45-17:45
oom: Lotus 1-4
nfectious diseases surveillance and alert systems
. Madoff
ProMED-mail, Boston, MA, USA
Prompt detection of infectious disease outbreaks is required
o ensure timely responses that reduce morbidity and mortality,
nd mitigate social and economic disruption. Traditional public
ealth surveillance systems rely on hierarchical structures where
roviders, laboratories and healthcare institutions report deﬁned
iseases to local authorities. Local authorities in turn report to
egional authorities that report to national ofﬁcials, who then
eport to international bodies such as WHO. While this system
as many strengths, it is expensive and has critical weaknesses as
ell e.g., slow reporting, inevitable breaks in the chain of commu-
ication, disincentives to report, and failure to report undeﬁned
r unrecognized illnesses. The past twenty years has seen enor-
ous innovation in nontraditional public health reporting systems.
roMED was perhaps the ﬁrst system to exploit the Internet to
llow nontraditional sources of health information such as media,
rsthand clinician and lay observer reports to be widely dissemi-
ated and serve as early warnings of outbreaks, thus encouraging
ransparency in detection and reporting of emerging disease and
ther biohazardous threats. It has enhanced reporting in under-
erved areas through the development of regional programs such
s PRO/MBDS in Southeast Asia. The growing “ﬁrehose” of data
hat can be mined for public health purposes has led to a num-
er of novel strategies for harnessing this information. GPHIN and
ealthMap utilize web crawling, coupled with human data cura-
ion, to rapidly reportdiseaseevents.Otherbiosurveillance systems
nclude Medisys and BioCaster. Deidentiﬁed search engine queries
rom Google and Yahoo, the so-called “searchstream,” have been
sed to monitor community levels of inﬂuenza and dengue. The
ontents of Twitter messages and other social media content can
egeolocated,monitored, analyzed, and interpreted to showtrends
n outbreaks and public sentiment regarding vaccination and other
ublic health interventions. Cell phone usage patterns can detect
nusual events such as disease outbreaks and can track patterns
f movements and migration. Cell phones themselves, now nearly
biquitous, have become tools for rapid reporting of health events.nfectious Diseases 16S (2012) e2–e157 e45
The revised International Health Regulations, enacted in 2005 and
adopted in 2007 have codiﬁed the use of informal information
sources and promote the rapid and transparent ﬂow of public
health data.
http://dx.doi.org/10.1016/j.ijid.2012.05.113
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A weak state health infrastructure and a disparate system of
rural clinics render thedeliveringof treatment and care ofHIV/AIDS
patients in sub-Saharan Africa extremely difﬁcult. Furthermore,
because patients living in remote areas do not have access to lab
facilities, we developed a decentralized strategy based on bringing
the needed services closer to the people, through the use of Ther-
apeutic Mobile Units (TMU) as potentially useful means to follow
up adults and children undergoing antiretroviral treatment.
Using the TMU of the National Public Health Laboratory of the
CameroonMinistry ofHealth,we conducted several cross-sectional
surveys on epidemiological, biological and clinical features of
HIV/AIDS in young and elderly patients in Cameroon. The screening
of HIV-speciﬁc antibodies was carried out using rapid tests. Inde-
terminate or positive samples were immediately retested. People
diagnosed as HIV-infected were provided free biological monitor-
ing and referred to health care centres. The TMU was also equipped
with the Auto40 cytometer for CD4 determination. A FACSCalibur
cytometer was used as reference method.
From April 2005 to July 2011, 120 campaigns were organised
in Cameroon (average of 277 volunteers tested per day). Out of
32, 970 volunteers who received a pre-test counselling, 32, 869
(20,937 males; 11,932 females) tested for HIV (acceptance rate of
99.69%). Their average age was 31 years. Amongst those, 32,569
(99.08%) received post-test counselling. The overall HIV prevalence
was 6.06% [with higher rates in women, data not shown]. CD4 test-
ing was performed using the Auto40 cytometer and gave a perfect
correlation with the reference method (FASCSCalibur) [mean±SD
CD4 T cell count was 1041±317 cells/ml by Auto40, and 1032±294
cells/ml by FACSCalibur; r2=0.982]. For patients receiving ART, our
medical staff provided support in monitoring treatment, recording
information about patient’s medical status, resolving the barriers
to drug adherence and others factors that may affect a patient ART
therapy (data not shown).
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accessible. In settings where with no VL and genotypic resistance
guided, TDF/3TC(or FTC)/LPv/r may be a suitable option.
http://dx.doi.org/10.1016/j.ijid.2012.05.11646 15th ICID Abstracts / International Journ
With nearly eighty percent of patients not receiving appropriate
are in Sub Saharan Africa, TMU likely constitutes a useful tool in
roviding large scale up HIV testing, biological monitoring, treat-
ent and care and should be integrated into national HIV control
rogrammes.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.114
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ew diagnostic tools for monitoring antiretroviral therapy in
esource limited settings
. Crowe
Burnet Institute, Melbourne, Australia
CD4 testing has traditionally been performed using a ﬂow
ytometer. In resource limited settings such testing requires a lab-
ratory, a relatively expensive instrument, a trained technician and
s associated with signiﬁcant loss to follow up as the patient has to
eturn for results.
The semi-quantitative Burnet CD4 test has been speciﬁcally
esigned for point of care use, performed with ﬁnger-prick blood,
ithout requiring any instrument or cold chain, by a health care
orker with minimal training. The results are available within 40
inutes. The test detects full-length CD4 protein associated with
-cells, and excludes CD4 on monocytes and soluble CD4 protein
n blood. The Burnet CD4 POC tests have been designed with an
nitial cutoff of 250 CD4/l (to provide a safety margin above the
reatment cutoff of 200 CD4/l) or a second generation test with
cut-off of 350 cells/ l, in keeping with recent WHO recommen-
ations. Early external validation indicates that the test is accurate
assessed by mis-classiﬁcation) when compared to ﬂow cytome-
ry. The test is anticipated to improve access to ART and loss to
ollow-up associated with having to return for results.
The Alere PIMATM POC CD4 test has recently been released.
t has a throughput of 20 tests+ per day, with a 20-30 minute
urnaround timeand requiresno cold chain. It requires adevice that
s portable andperformswellwhencomparedwithﬂowcytometry.
Even in resource-constrained settings, it is generally agreed that
iral load testing is essential for accurate and early detection of a
oor response to ART. Identifying treatment failure early enables
atient adherence counseling and may permit patients to continue
n 1st-line cART, avoiding unnecessary switches to more expen-
ive 2nd-line regimens. Current HIV viral load testing methods
sing nucleic-acid ampliﬁcation are expensive, require sophisti-
ated equipment and signiﬁcant technical expertise and dedicated
aboratory facilities to prevent contamination,making themgener-
lly unsuitable forwidespread use in resource-constrained regions.
ncreased access to ART has highlighted the need for suitable low
ost viral load testing.
Cavidi ExaVirTMLoad v 3 is a low cost, relatively technically
imple HIV viral load assay based on reverse transcriptase quantiﬁ-
ation. The assay has a sensitivity of about 200 copies/ml, detects
ll HIV-1 and HIV-2 variants and results correlate well with Roche
OBASAmplicorTM assay.nfectious Diseases 16S (2012) e2–e157
There are several other POC CD4 (eg Zyomyx) and VL assays (eg
SAMBATM) under development that may be available in the next
few years; preliminary information will be provided.
http://dx.doi.org/10.1016/j.ijid.2012.05.115
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Management of antiretroviral therapy failure in resource lim-
ited settings
K. Ruxrungtham
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
HAART inresource-limitedsettings(RLS):Approximately>80%
of 34 million HIV-infected patients were living inlow- and middle-
income countries, andat least 6.6 million were on HAART. Most
patients in RLS are treated with NNRTI-based regimen, nevirap-
ine+3TC+AZT or d4T in particular. Several studies either in Africa
or Asia have shown the viral success rate (plasma VL<50-400 c/ml)
was varied from 70%-90% (ITT analyses). The two most common
causes of treatment failure are non-adherence and drug-related
toxicity. Other factors including late diagnosis with advanced dis-
ease, very low CD4 cell counts and high viral load at baseline. In
most RLS, only CD4 count is available for treatment monitor, VL
and drug resistance genotypic tests are not accessible due to the
cost constraint. As a result, HAART failure has therefore been asso-
ciatedwith a verymuchdelayed in detecting failure comparedwith
the use of pVL as a monitoring test.
Drug resistance: Extensively exposed to the failing regimenwill
lead to more cross resistance. Early virologic failure(<6 months),
only 3TC or FTC resistance (M184V) and or NNRTI-resistance will
be detected. In contrast, late failure will result to an accumulation
of thymidine-analog mutations (TAMs) and eventually to a cross
resistance to both the NNRTI and NRTI classes.
Treatment options after NNRTI failure: The principle in select-
ing a new second-line option is to use ideally 3 new active ARVs in
the regimen. In reality, ARV options are very limited and also DR
genotypic test is not available to guide for active ARV selection.
Recently only one randomized trial, HIV-STAR has been reported.
In this study, almost all patients had 3TC and NNRTI-resistance.
A half had any of TAMs (TAM2:TAM1 3:1). The results showed a
signiﬁcant inferior of mono-LPV/r compared with when in combi-
nation with TDF/3TC (61% vs 83%, p<0.01). Thus mono-LPV/r is not
recommended.
Conclusions: Expanded access to HAART is essential to ﬁght
against the AIDS epidemic, however to early detect poor adherence
and treatment failure, it is anurgentneed toalsomakingpVLwidely
